Search results
5 days ago · Marks spoke little about Sarepta Therapeutics’ Elevidys, the first approved gene therapy for Duchenne. Elevidys is currently only available for certain 4- to 5-year-old boys under an conditional approval granted by the FDA last June. By June 21, though, the agency could convert that clearance to full approval and authorize use more widely.
1 day ago · The cystic fibrosis transmembrane conductance regulator (CFTR) is a crucial ion channel whose loss of function leads to cystic fibrosis, whereas its hyperactivation leads to secretory diarrhea. Small molecules that improve CFTR folding (correctors) or function (potentiators) are clinically available. However, the only potentiator, ivacaftor ...
6 days ago · May 23 (UPI) --A panel of U.S. Food and Drug Administration advisers on Thursday recommended approval for a new blood test to detect colon and rectal cancer despite concerns over the test's...
5 days ago · Chief Executive Officer. ASIFMA. Peter Stein is the Chief Executive Officer of ASIFMA. Reporting to the Board of Directors, he leads the association’s vision and strategy as it advocates on behalf of its over 160 member firms for the efficient growth and development of Asia’s capital markets.
5 days ago · May 24, 2024 - 10:38 AM. The Food and Drug Administration May 23 announced that Medline Industries, a firm marketing and distributing Chinese-manufactured plastic syringes within the U.S., initiated a recall to stop using affected products, including unauthorized plastic syringes made in China.
1 day ago · North Carolina Attorney General Josh Stein and the U.S. Attorney’s Office for the Middle District of North Carolina have reached a $500,000 settlement with Sharon Raynes Halliday and RAPHA Healthcare Services LLC, resolving a false claims lawsuit filed in July 2022 related to requests for payment submitted to the North Carolina Medicaid program.
5 days ago · There are two principal forms of hyperbolae: The first describes the relation between response rate and reinforcement rate on variable-interval schedules of reinforcement; it rises asymptotically toward a maximum. The second describes the relation between the current equivalent value of an incentive and its delay or (im)probability; it falls ...
